ERAS · Erasca, Inc. · Metrics
$13.61
-0.61 (-4.29%)
At close · Nov 20
Return incl. dividend (before tax)
Q4 2023 earnings call transcript
Market Cap
$4.78B
Shares
350.96M
Volume · Nov 20
11.07M
Avg daily vol (3M)
5.23M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
ERAS metrics
71 of 125 screener metrics currently available.
Market overview
2 metricsShare price
$13.61
Market cap
$4.78B
Price action
23 metricsPrice change (1W)
-13.1%
Price change (30D)
-3.1%
Price change (3M)
-22.8%
Price change (6M)
+21.1%
Price change (YTD)
+265.9%
Price change (1Y)
+389.6%
Trailing year
Price change (5Y)
-24.5%
52-week high
$22.47
52-week low
$2.78
Change from 52-week high
-39.4%
Change from 52-week low
+389.6%
Annualized volatility
102.7%
Annualized volatility (3M)
70.4%
Implied volatility (30D)
134.8%
IV rank (1Y)
45.4
IV percentile (1Y)
86.7
Beta
1.7
RSI (14D)
42.7
Price vs SMA 50
-7.8%
Price vs SMA 200
-11.2%
Avg volume (3M)
5.23M
Relative volume
2.1
Average dollar volume
$79.82M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
350.96M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
5.2
reciprocal yield 19.2%
FCF yield
-2.3%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-6.4%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2024-05-08
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$327.65M
Net income (TTM)
−$307.94M
Trailing 12 months
Diluted EPS (TTM)
$-0.99
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+21.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-33.6%
Return on assets
-30.8%
Debt / equity
0.0
Current ratio
14.9
EBITDA (TTM)
—
Free cash flow (TTM)
−$109.24M
Quick ratio
14.9
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$643.70M
Latest balance sheet
Cash & equivalents
$118.96M
Total assets
$998.94M
Total debt
$0
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$109.11M
Capital expenditures (TTM)
$132,000
R&D (TTM)
$133.60M
SG&A (TTM)
—
Stock compensation (TTM)
$35.82M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
272
13F filer change QoQ
+15
Institutional ownership
93.2%
Conviction holders (share of 13F filers)
4.8%
Crowding (high-turnover and private-fund holders)
50.0%
Private-fund adviser ownership
47.5%
Active holders' share change QoQ
+16.3%
Holder tenure
9.4
Price vs estimated holder cost
+54.1%
Ownership (registered funds)
1 metricsIndex-fund ownership
11.3%
Short interest
3 metricsShort interest
10.6%
Latest settlement · 8.9 days to cover
Days to cover
8.9d
Short-squeeze score
77 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—
Key facts
CIK
1761918
CUSIP
29479A108
13F (30d)
282 filings
260 filers
Visit website
Investor relations